SCHEMBL2944141

SCHEMBL2944141

CC(C)(C)OC(=O)N1CCC(CO)(Nc2ccc(S(N)(=O)=O)cc2[N+](=O)[O-])CC1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.51
GAA P10253 7/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 2/20 0.51
HTT P42858 1/20 0.51
GPR119 Q8TDV5 2/20 0.47
PKM P14618 2/20 0.45
KMT2A Q03164 1/20 0.45
BCL2 P10415 1/20 0.43
BCL2L1 Q07817 1/20 0.43
POLB P06746 1/20 0.41
NPSR1 Q6W5P4 2/20 0.41
JAK2 O60674 2/20 0.41
JAK1 P23458 2/20 0.41
MAPK1 P28482 1/20 0.41
MMP13 P45452 2/20 0.40
ADAM17 P78536 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MMP2 P08253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1959604 0.88 MAPT (0.51) MAPTGAALMNAALDH1A1HTT
SCHEMBL2952145 0.87 BCL2L1 (0.52) MAPTGAALMNAALDH1A1HTT
SCHEMBL22581464 0.83 MAPT (0.50) MAPTGAALMNAALDH1A1HTT
SCHEMBL30414834 0.83 MAPT (0.50) MAPTGAALMNAALDH1A1HTT
SCHEMBL1700248 0.81 MAPT (0.53) MAPTGAALMNAALDH1A1HTT
SCHEMBL1700051 0.79 MAPT (0.52) MAPTGAALMNAALDH1A1HTT
SCHEMBL31344646 0.79 MAPT (0.52) MAPTGAALMNAALDH1A1HTT
SCHEMBL3595619 0.79 GPR119 (0.56) MAPTLMNAALDH1A1GPR119BCL2
SCHEMBL21751622 0.79 BCL2 (0.52) MAPTGAALMNAALDH1A1HTT
SCHEMBL19503741 0.79 MAPT (0.51) MAPTGAALMNAALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7754886-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2010-07-13 US disclosed
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LABORATORIES (US) 2009-05-28 US disclosed
US-7504512-B2 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES (US) 2009-03-17 US disclosed
EP-1318978-B1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS ABBOTT LAB (US) 2006-02-08 EP disclosed
US-20040192681-A1 N-acylsulfonamide apoptosis promoters ABBVIE INC. 2004-09-30 US disclosed
US-20020055631-A1 N-acylsulfonamide apoptosis promoters ABBOTT LABORATORIES 2002-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020055631-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4830/4885GAA 3136/4885LMNA 456/4885
US-20040192681-A1 N-acylsulfonamide apoptosis promoters BAX, BCLAF1, BCL2 MAPT 4851/4885GAA 2935/4885LMNA 472/4885
US-20090137585-A1 N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS BAX, BCL2, BCOR MAPT 4806/4885GAA 2772/4885LMNA 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.